The present disclosure discloses use of mesenchymal stem cells in preparation of a formulation for promoting fat transplantation, relating to the field of biotechnologies. The inventors found through research that compared with MSCs derived from somatic cells, MSCs derived from human pluripotent stem cells have more stable quality, are not affected by donor's physical quality, disease and treatment process, and can promote fat transplantation by enhancing tissue remodeling, angiogenesis and adipose cell survival and decreasing tissue fibrosis.

The invention provides a method of promoting reprogramming of a cardiac fibroblast into a cardiomyocyte by contacting the cardiac fibroblast with an isolated polynucleotide molecule comprising at least two functional miRNA sequences using a multicistronic expression system for reprogramming of fibroblasts into functional mature cardiomyocytes.

The invention relates to induced pluripotent stem cells (iPSCs) produced from source dendritic cells (DCs). The invention also relates to synthetic DCs re-differentiated the iPSCs and which display a definitive adult phenotype rather than a primitive fetal/neonatal phenotype. The invention also relates to methods for making and methods of using the iPSCs and DCs of the invention.

The present disclosure relates generally to methods and compositions useful in cell and tissue biology and therapeutics. In particular, an in vitro method for differentiating pluripotent stem cells into KDR.sup.+NCAM.sup.+APLNR.sup.+ mesoderm cells and/or SSEA5.sup.−KDR.sup.+NCAM.sup.+APLNR.sup.+ mesoderm cells is provided. The disclosed mesoderm cells may be used to generate blood vessels in vivo and/or further differentiated in vitro into endothelial colony forming cell-like cells (ECFC-like cells). Purified human cell populations of KDR.sup.+NCAM.sup.+APLNR.sup.+ mesoderm cells and ECFC-like cells are provided. Test agent screening and therapeutic methods for using the cell populations of the present disclosure are provided.

The present invention relates to an in vitro method for predicting the proangiogenic activity of preparations of extracellular vesicles (EVs), preferably blood-derived EVs, wherein the method is based on the combined determination of the content of transforming growth factor beta (TGFβ) and microRNA-130a. Also disclosed is a method of manufacturing a preparation of extracellular vesicles (EVs) predicted to have strong proangiogenic activity and the EVs preparations thereof, which are effective for the therapeutic treatment of ischemic diseases, ischemic injuries and pathological conditions associated with risk of cardiovascular disease, or for use in wound healing.

Described herein are methods and compositions related to methods of improving survival and engraftment of human cells differentiated in vitro, and uses thereof.

The present disclosure concerns methods and compositions for generation of induced pluripotent stem cells with increased efficiency and genome stability. In particular aspects, induced pluripotent stem cells are generated from somatic cells following inhibition, reduction or downregulation of a particular protein or gene. In some embodiments, the protein is p53-binding protein or 53BP1.

Provided herein are compositions of lipid-based nanoparticles, such as exosomes, that comprise a therapeutic anti-aging agent. Also provided are methods of using such compositions to treat a patient having an age-associated disorder. In particular, exosomes comprising a telomerase-encoding RNA are provided along with methods of their use in treating age-associated disorders.

The invention provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating and preventing metastasis or relapse of a cancer in an individual previously treated for cancer with a therapy. The invention also provides oligonucleotides complementary to a non-coding chimeric mitochondrial RNA as well as compositions and kits comprising the same, and their use in treating a refractory cancer (e.g., a refractory HPV-associated cancer).

A method for inducing non-hepatocytes into hepatocyte-like cells, wherein the non-hepatocytes are induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte expansion culture medium and 2C medium for a sufficient period of time to convert the non-hepatocyte cell into cells with hepatocyte-like properties, are provided. The iHeps induced according to the methods are also provided.